References
- World Health organization, Epilepsy: Available from: http://www.who.int/mediacentre/factsheets/fs999/en/
- Klitgard H. Epilepsy therapy: anticonvulsants, lessons learned and unmet medical needs. Interview by Rona Williamson. Expert Rev Neurother 2013;13:13–4
- Picot MC, Baldy-Moulinier M, Daurs JP, et al. The prevalence of epilepsy and pharmacoresistant epilepsy in adults: a population-based study in a Western European country. Epilepsia 2008;49:1230–8
- Wilcox KS, Dixon-Salazar T, Sills GJ. Issues related to development of new antiseizure treatments. Epilepsy 2013;54:24–34
- Cramer JA, Mintzer S, Wheless J, Mattson RH. Adverse effects of antiepileptic drugs: a brief overview of important issues. Expert Rev Neurother 2010;10:885–91
- Khan HN, Kulsoom S, Rashid H. Ligand based pharmacophore model development for the identification of novel antiepileptic compound. Epilepsy Res 2012;98:62–71
- Wong MG, Defina JA, Abdrews PR. Conformational analysis of clinically active anticonvulsant drugs. J Med Chem 1986;29:562–72
- Tasso SM, Bruno-Blanch LE, Moon SC, Estiu GL. Pharmacophore searching and QSAR analysis in the design of anticonvulsant drugs. J Mol Struct 2000;504:229–40
- Obniska J, Chlebek I, Kamiński K, et al. Synthesis and anticonvulsant properties of new N-Mannich bases derived from 3,3-diphenyl-and 3-ethyl-3-methyl-pyrrolidine-2,5-diones. Part III. Arch Pharm Chem Life Sci 2013;346:71–82
- Rybka S, Obniska J, Rapacz A, et al. Synthesis physicochemical and anticonvulsant properties of new N-Mannich bases derived from pyrrolidine-2,5-dione and its 3-methyl analog. Arch Pharm Chem Life Sci 2014;347:1–9
- Obniska J, Rzepka S, Kamiński K. Synthesis and anticonvulsant activity of new N-Mannich bases derived from 3-(2-fluorophenyl)-and 3-(2-bromophenyl)-pyrrolidine-2,5-diones. Part II. Bioorg Med Chem 2012;20:4872–80
- Kamiński K, Obniska J, Chlebek I, et al. Synthesis and anticonvulsant activity of new 1-[2-oxo-2-(4-phenylpiperazin-1-yl)-ethyl]pyrrolidine-2,5-diones. Bioorg Med Chem Lett 2011;21:5800–3
- Kamiński K, Obniska J, Wiklik B, Atamanyuk D. Synthesis and anticonvulsant properties of new acetamide derivatives of phthalimide, and its saturated cyclohexane and norbornene analogs. Eur J Med Chem 2011;46:4634–41
- Miller CA, Long LM. An investigation of N-R-α-R1-α-phenylsuccinimides. J Am Chem Soc 1951;73:4895–8
- Kupferberg HJ. Antiepileptic drug development program: a cooperative effort of government and industry. Epilepsia 1989;30:51–6
- Dunham NW, Miya TA. A note on a simple apparatus for detecting neurological deficit in rats and mice. J Am Pharm Assoc Am Pharm Assoc 1957;46:208–9
- Brown WC, Schiffman DO, Swinyard EA, Goodman LS. Comparative assay of an antiepileptic drugs by psychomotor seizure test and minimal electroshock threshold test. J Pharmacol Exp Ther 1953;107:273–83
- Kaminski RF, Livingood MR, Rogawski MA. Allopregnanolone analogs that positively modulate GABA receptors protect against partial seizures induced by 6-Hz electrical stimulation in mice. Epilepsia 2004;45:864–7
- Brown GB. 3H-batrachotoxinin – a benzoate binding to voltage-sensitive sodium channels: inhibition by the channel blockers tetrodotoxin and saxitoxin. J Neurosci 1986;6:2064–700
- Gould RJ, Murphy KM, Snyder SH. [3H] nitrendipine-labeled calcium channels discriminate inorganic calcium agonists and antagonists. Proc Natl Acad Sci USA 1982;79:3656–60
- Löscher W. Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. Seizure 2011;20:359–68
- Rowley NM, White HS. Comparative anticonvulsant efficacy in the corneal kindled mouse model of partial epilepsy: correlation with other seizure and epilepsy models. Epilepsy Res 2010;92:163–9
- Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci 2004;5:553–64
- Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res 2009;83:1–43
- Meldrum BS, Rogawski MA. Molecular targets for antiepileptic drug development. Neurotherapeutics 2007;4:18–61
- Liu G, Yarov-Yarovoy V, Nobbs M, et al. Differential interactions of lamotrigine and related drugs with transmembrane segment IVS6 of voltage-gated sodium channels. Neuropharmacology 2003;44:413–22
- Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 2000;41:3–9
- Steinlein OK. Calcium signaling and epilepsy. Cell Tissue Res 2014;357:385–93
- Thirumurugan R, Sriram D, Saxena A, et al. 2,4-Dimethoxyphenylsemicarbazones with anticonvulsant activity against three animal models of seizures: synthesis and pharmacological evaluation. Bioorg Med Chem 2006;14:3106–12
- White HS, Woodhead JH, Wilcox KS, et al. Antiepileptic drugs. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Philadelphia: Lippincott; 2002:43–4